G. Bubley

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

G. Bubley, S. Balk, M. Taplin, 1995, The New England journal of medicine.

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

J. Manola, M. Loda, P. Kantoff, 2000, Journal of the National Cancer Institute.

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.

G. Bubley, A. Chott, Zijie Sun, 1999, The American journal of pathology.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

B. Freidlin, H. Scher, W. Oh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is the flare phenomenon clinically significant?

G. Bubley, G. Bubley, 2001, Urology.

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

D. Rosenthal, G. Bubley, S. Come, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of circulating tumor cells in men with localized prostate cancer.

P. Kantoff, I. Kaplan, G. Bubley, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromium(VI) treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of cell cycle.

G. Bubley, S. Patierno, Jian Xu, 1996, Carcinogenesis.

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

S. Taneja, E. Small, G. Bubley, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone.

E. Small, G. Bubley, C. Logothetis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

P. Kantoff, W. Oh, G. Bubley, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.